Kite Pharma, Inc. Announces Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor T Cells 10 of the patients who had an MRD-negative complete response subsequently underwent hematopoietic stem-cell transplantation, and all 10 remained disease free upon 10-month follow-up.
http://ift.tt/1qjAIaB
http://ift.tt/1qjAIaB
No comments:
Post a Comment